期刊名称：THERAPEUTIC ADVANCES IN HEMATOLOGY ISSN： 2040-6207 出版频率： Continuous publication 出版社： SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP   出版社网址： https://journals.sagepub.com/ 期刊网址： https://journals.sagepub.com/home/taha 影响因子： 7.167 主题范畴： HEMATOLOGY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims and Scope Therapeutic Advances in Hematology delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of blood disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in hematology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of hematology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies - all phases. Letters to the Editor and Case Reports will also be considered. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; online publication is usually within 3 weeks of Acceptance. Abstracting and Indexing This journal is included in the following abstracting and indexing databases. Clarivate Analytics: Current Contents - Life Sciences Clarivate Analytics: Science Citation Index Expanded (SCIE) Directory of Open Access Journals (DOAJ) ProQuest PubMed Central (PMC) Instructions to Authors Manuscript Submission Guidelines:  Manuscript Submission Guidelines: Therapeutic Advances in Hematology  This Journal is a member of the Committee on Publication Ethics. This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE). Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/tah to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process. Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Hematologywill be reviewed. As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you. Therapeutic Advances in Hematology may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper. Citing preprints is permitted if no peer reviewed version of the article has been published. Open Access Article processing charge (APC) What do we publish? 3.1 Aims &Scope 3.2 Article Types 3.3 Writing your paper Editorial policies 4.1 Peer Review Policy 4.2 Authorship 4.3 Acknowledgements 4.4 Funding 4.5 Declaration of conflicting interests 4.6 Research ethics and patient consent 4.7 Clinical Trials 4.8 Reporting guidelines 4.9 Data Publishing policies 5.1 Publication ethics 5.2 Contributor's publishing agreement  Preparing your manuscript 6.1 Word processing formats 6.2 Artwork, figures and other graphics 6.3 Supplementary material 6.4 Reference style 6.5 English language editing services Submitting your manuscript 7.1 ORCID 7.2 Information required for completing your submission 7.3 Permissions On acceptance and publication 8.1 SAGE Production 8.2 Continuous publication 8.3 Promoting your article Further information  Editorial Board   Managing Editor Alessandro Baliani SAGE Publications Ltd, UK Associate Editors Brian Hill Taussig Cancer Institute, Clevelan, OH, USA Cedric Hermans St-Luc University Hospital, Brussels, Belgium Elias Jabbour M.D. Anderson Cancer Center, Houston, TX, USA Michaela Liedtke Stanford Cancer Institute, Stanford, CA, USA Editorial Board Mark Alderson Path, Seattle, USA Guillermo Montalban Bravo MD Anderson Cancer Center, Houston, TX, USA Graham Collins Oxford University Hospitals, Oxford, UK Jorge Cortes M.D. Anderson Cancer Center, Houston, TX, USA Myron Czuczman Roswell Park Cancer Institute, Buffalo, NY, USA Elliot Epner Penn State Hershey Cancer Institute, Hershey, PA, USA Elihu Estey Seattle Cancer Center Alliance, Seattle, WA, USA Stefan Faderl Hackensack University Medical Center, Hackensack, NJ, USA Alessandra Ferrajoli M.D. Anderson Cancer Center, Houston, TX, USA Patrick Fogarty University of Pennsylvania, Philadelphia, PA, USA Guillermo Garcia-Manero M.D. Anderson Cancer Center, Houston, TX, USA Amy Geddis Moores Cancer Center, San Diego, CA, USA Terry Gernsheimer University of Washington School of Medicine, Seattle, WA, USA Katharina Gotze Technical University of Munich, Munich, Germany Eric Grabowski Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Elizabeth Hexner Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA Ulrich Keller Technical University of Munich, Munich, Germany Maya Koren-Michowitz Assaf Harofeh Medical Center, Zeriffin, Israel Karl-Anton Kreuzer University of Cologne, Germany Hillard Lazarus Case Western Reserve University, Cleveland, OH, USA Georg Lenz University Hospital Münster, Münster, Germany Howard Liebman University of Southern California - Keck School of Medicine, Los Angeles, CA, USA Eduardo Olavarria Imperial College London at hammersmith Hospital, London, UK Johnny N. Mahlangu University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa Keith McCrae Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA Neha Mehta-Shah Washington University Medical School, St. Louis, MO, USA Massimo Morfini Italian Association of Hemophilia Centers (AICE), Milan, Italy Stephen Oh Washington University School of Medicine, St. Louis, MO, USA Bipin Savani Vanderbilt University Medical Center, Nashville, TN, USA Deborah Thomas M.D. Anderson Cancer Center, Houston, TX, USA Peter Valent Medical University of Vienna, Vienna, Austria Alessandro Vannucchi University of Florence, Florence, Italy Nikolas von Bubnoff Freiburg University Medical Center, Freiburg, Germany Jianxiang Wang Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Guy Young University of Southern California-Keck School of Medicine, Los Angeles, CA, USA